Liporosa

Ezetimibe and rosuvastatin zinc, the active ingredients in Liporosa, are a statin and cholesterol absorption inhibitor presented as a tablet for oral use. It reduces LDL‑cholesterol in adults with hypercholesterolemia or mixed dyslipidemia and is used for primary prevention of cardiovascular disease.

GNH USA supplies Liporosa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Liporosa acts on lipid metabolism pathways to lower abnormal cholesterol levels. - Hypercholesterolemia: lowers LDL‑cholesterol and total cholesterol. - Mixed dyslipidemia: reduces both LDL‑cholesterol and triglycerides while modestly raising HDL‑cholesterol. - Primary prevention of cardiovascular disease: helps decrease the risk of heart attack and stroke in patients with elevated lipid profiles.

Liporosa may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild to moderate intensity. - Abdominal pain: discomfort in the stomach area. - Diarrhea: loose stools occurring intermittently. - Muscle aches: mild myalgia without weakness. - Elevated liver enzymes: mild increase in ALT/AST. - Nausea: feeling of queasiness.

Serious or Rare Side Effects: - Rhabdomyolysis: severe muscle breakdown with dark urine. - Acute liver injury: marked elevation of liver enzymes with jaundice. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Myopathy: muscle weakness with elevated CK levels. - Pancreatitis: abdominal pain with elevated pancreatic enzymes. - Hepatotoxicity: liver failure requiring medical intervention.

Before initiating Liporosa, clinicians should evaluate patient-specific risk factors and monitor relevant laboratory parameters. - Liver function monitoring: check ALT/AST before treatment and periodically thereafter. - Muscle symptom assessment: inquire about unexplained muscle pain or weakness. - Renal function evaluation: adjust use in patients with severe renal impairment. - Drug interaction review: assess concomitant medications that may increase statin exposure. - Pregnancy and lactation: avoid use unless clearly indicated by a physician. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Liporosa can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Cyclosporine: markedly increases rosuvastatin plasma concentrations. - Gemfibrozil: raises risk of myopathy and rhabdomyolysis. - Strong OATP1B1 inhibitors (e.g., rifampin): elevate rosuvastatin levels.

Moderate Interactions (Monitor Closely): - Amlodipine: may increase rosuvastatin exposure modestly. - Antacids containing aluminum or magnesium: can reduce ezetimibe absorption. - Niacin: may increase risk of liver enzyme elevation. - Fibrates (e.g., fenofibrate): monitor for additive lipid‑lowering effect and muscle toxicity. - Digoxin: observe for potential increased serum concentrations.